CD46 Null Packaging Cell Line Improves Measles Lentiviral Vector Production and Gene Delivery to Hematopoietic Stem and Progenitor Cells
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 13, 27-39
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (2U54GM103368, 2P30AI036214, 1R01HL116221)
This publication has 50 references indexed in Scilit:
- Gene Therapy in a Patient with Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Lentiviral vectors, two decades laterScience, 2016
- Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin GeneHuman Gene Therapy, 2016
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich SyndromeScience, 2013
- LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virusProceedings of the National Academy of Sciences, 2013
- Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivoNature Biotechnology, 2010
- Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked AdrenoleukodystrophyScience, 2009
- Endosome-to-cytosol transport of viral nucleocapsidsNature Cell Biology, 2005
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996